Capricor sues partner Nippon Shinyaku in DMD therapy spat

Capricor Therapeutics has fallen out with its commercial partner for Duchenne muscular dystrophy (DMD) cell therapy deramiocel, Nippon Shinyaku, and is taking its complaint to the courts.

The San Diego biotech has filed a lawsuit against the Japanese drugmaker and its US subsidiary, NS Pharma, claiming that the terms of their distribution contract for deramiocel are flawed and could hinder DMD patients from getting access to the therapy if it gets approved by the FDA.

According to Capricor, the distribution agreement with NS Pharma contains a “fundamental pricing flaw” that its partner has…